Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease","authors":"Masahiro Sogabe ,&nbsp;Toshiya Okahis ,&nbsp;Miwako Kagawa ,&nbsp;Motoko Sei ,&nbsp;Hiroyuki Ueda ,&nbsp;Reiko Yokoyama ,&nbsp;Kaizo Kagemoto ,&nbsp;Hironori Tanaka ,&nbsp;Yoshifumi Kida ,&nbsp;Fumika Nakamura ,&nbsp;Tetsu Tomonari ,&nbsp;Koichi Okamoto ,&nbsp;Hiroshi Miyamoto ,&nbsp;Yasushi Sato ,&nbsp;Masahiko Nakasono ,&nbsp;Tetsuji Takayama","doi":"10.1016/j.dsx.2024.103036","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103036","url":null,"abstract":"<div><h3>Aims</h3><p>Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes.</p></div><div><h3>Methods</h3><p>Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with &gt;2 health checkups over &gt;2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage.</p></div><div><h3>Results</h3><p>Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (<em>p</em> &lt; 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m² and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (<em>p</em> &lt; 0.01 and <em>p</em> &lt; 0.001, respectively).</p></div><div><h3>Conclusions</h3><p>Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103036"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140950168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of cardiovascular disease attributable to high fasting plasma glucose：Findings from the global burden of disease study 2019","authors":"Xin-Jiang Dong ,&nbsp;Xiao-Qi Zhang ,&nbsp;Bei-Bei Wang ,&nbsp;Fei-Fei Hou ,&nbsp;Yang Jiao","doi":"10.1016/j.dsx.2024.103025","DOIUrl":"10.1016/j.dsx.2024.103025","url":null,"abstract":"<div><h3>Aim</h3><p>High fasting plasma glucose (HFPG) is a key risk factor for cardiovascular disease (CVD). Few studies have evaluated the CVD burden attributable to HFPG globally. It is urgent to investigate the current epidemiological pattern and past trends of CVD attributable to HFPG.</p></div><div><h3>Methods</h3><p>We used the Global Burden of Disease Study (GBD) 2019 to describe the CVD burden attributable to HFPG in 2019 and evaluate temporal trends between 1990 and 2019.</p></div><div><h3>Results</h3><p>Global Disability-Adjusted Life Years (DALYs) cases and death cases of HFPG-related CVD were approximately 72,591,163 and 3,763,298 in 2019, with an increase of 107.4 % and 114.6 % compared with 1990, respectively. Despite the increases, the age-standardized DALYs rate (ASDAR) and age-standardized death rate (ASDR) of HFPG-related CVD contributed to 895.2 per 100,000 people and 48.4 per 100,000 people in 2019, with an estimated annual percentage change (EAPC) of −0.22 and −0.31, respectively, from 1990. The highest ASDAR and ASDR of HFPG-related CVD were in 2019 observed in the low-middle SDI (Socio‐demographic Index) and middle-SDI regions. Low SDI and some low-middle SDI regions showed an increase in ASDAR and ASDR of HFPG-related CVD from 1990 to 2019. Males are more affected by HFPG-related CVD than females across all years. The CVD burden attributable to HFPG in the elderly are higher than those in the young in 2019. The main causes of the global CVD burden attributable to HFPG in 2019 were ischemic heart disease, stroke, and peripheral arterial disease.</p></div><div><h3>Conclusion</h3><p>The CVD burden attributable to HFPG remains a serious public health challenge threatening human health worldwide. It is necessary to develop more targeted and specific strategies to reduce CVD burden attributable to HFPG, especially in males, elderly, and lower SDI regions.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103025"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141049408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sarcopenic obesity on heart failure in people with type 2 diabetes and the role of metabolism and inflammation: A prospective cohort study","authors":"Xueqing Jia ,&nbsp;Liming Zhang ,&nbsp;Zhenqing Yang ,&nbsp;Xingqi Cao ,&nbsp;Zhao Yao ,&nbsp;Jingyun Zhang ,&nbsp;Zuobing Chen ,&nbsp;Zuyun Liu","doi":"10.1016/j.dsx.2024.103038","DOIUrl":"10.1016/j.dsx.2024.103038","url":null,"abstract":"<div><h3>Aims</h3><p>We aimed to prospectively evaluate the association of sarcopenic obesity (SO) with the incidence risk of heart failure (HF), and the mediating role of metabolomics and inflammation in people with type 2 diabetes (T2D).</p></div><div><h3>Methods</h3><p>22,496 participants with T2D from the UK Biobank were included. SO was defined as the combination of obesity (body mass index ≥30 kg/m²) and sarcopenia (grip strength &lt;27 kg in male or &lt;16 kg in female). The incident HF was identified through linked hospital records. Cox proportional hazard regression models were used to estimate the associations. Mediation analysis was conducted to evaluate the mediating effect of the “metabolomic risk score” of HF, which was derived from 168 plasma metabolites through LASSO regression, and five inflammatory markers (e.g., C-reactive protein [CRP] level) on the aforementioned associations.</p></div><div><h3>Results</h3><p>1946 (8.7 %) participants developed HF during a median follow-up of 12.0 years. Compared to participants with neither obesity nor sarcopenia, those with obesity &amp; non-sarcopenia (hazard ratio [HR]: 1.80, 95 % confidence interval [CI]: 1.62, 2.00), sarcopenia &amp; non-obesity (HR: 1.90, 95 % CI: 1.56, 2.31) and SO (HR: 2.29, 95 % CI: 1.92, 2.73) showed a higher risk of HF. The metabolomic risk score (20.0 %) and CRP (20.4 %) meditated this association.</p></div><div><h3>Conclusions</h3><p>SO was associated with an increased risk of HF in people with T2D and metabolomics and inflammation partially mediated this association. Our findings suggest the importance of managing obesity and muscle strength simultaneously in preventing HF among people with T2D and shed light on the underlying mechanisms.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103038"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk assessment of diabetes using the Indian Diabetes Risk Score among older adults: Secondary analysis from the Longitudinal Ageing Study in India","authors":"Saurav Basu ,&nbsp;Vansh Maheshwari ,&nbsp;Debolina Roy ,&nbsp;Mahira Saiyed ,&nbsp;Rutul Gokalani","doi":"10.1016/j.dsx.2024.103040","DOIUrl":"10.1016/j.dsx.2024.103040","url":null,"abstract":"<div><h3>Background</h3><p>The Indian Diabetes Risk Score (IDRS) is a simple tool to assess the probability of an individual having type 2 diabetes (T2DM) but its applicability in community-dwelling older adults is lacking. This study aimed to estimate the risk of T2DM and its determinants among older adults without prior diabetes (DM) using the IDRS, while also assessing its sensitivity and specificity in individuals with a history of diabetes.</p></div><div><h3>Methods</h3><p>We analyzed cross-sectional data from the Longitudinal Ageing Study in India (LASI) wave-1 (2017-18). IDRS was calculated amongst individuals aged ≥45 years considering waist circumference, physical activity, age and family history of DM. Risk was categorized as high (≥60), moderate (30–50), and low (&lt;30).</p></div><div><h3>Results</h3><p>Among 64541 individuals, 7.27 % (95 % CI: 6.78, 7.80) were at low risk, 61.80 % (95 % CI: 60.99, 62.61) at moderate risk, and 30.93 % (95 % CI: 30.19, 31.67) at high risk for T2DM. Adjusted analysis showed higher risk of T2DM among men, widowed/divorced, urban residents, minority religions, overweight, obese, and individuals with hypertension. ROC curve yielded an AUC of 0.67 (95 % CI: 0.66, 0.67, P &lt; 0.001). The IDRS cutoff ≥50 had 73.69 % sensitivity and 51.40 % specificity for T2DM detection.</p></div><div><h3>Conclusion</h3><p>More than 9 in 10 older adults in India without history of DM have high-moderate risk of T2DM when assessed with the IDRS risk-prediction tool. However, the low specificity and moderate sensitivity of IDRS in existing DM cases constraints its practical utility as a decision tool for screening.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103040"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of waist-to-height ratio, waist circumference and body mass index in predicting clustered cardiometabolic risk factors and subclinical vascular phenotypes in children and adolescents: A pooled analysis of individual data from 14 countries","authors":"Xin'nan Zong ,&nbsp;Roya Kelishadi ,&nbsp;Hae Soon Kim ,&nbsp;Peter Schwandt ,&nbsp;Tandi E. Matsha ,&nbsp;Jose G. Mill ,&nbsp;Peter H. Whincup ,&nbsp;Lucia Pacifico ,&nbsp;Abel López-Bermejo ,&nbsp;Carmelo Antonio Caserta ,&nbsp;Carla Campos Muniz Medeiros ,&nbsp;Wei-Li Yan ,&nbsp;Anastasios Kollias ,&nbsp;Paula Skidmore ,&nbsp;Liane Correia-Costa ,&nbsp;A. Khadilkar ,&nbsp;Fariborz Sharifian Jazi ,&nbsp;Zhuo Gong ,&nbsp;Cheng Zhang ,&nbsp;Costan G. Magnussen ,&nbsp;Bo Xi","doi":"10.1016/j.dsx.2024.103042","DOIUrl":"10.1016/j.dsx.2024.103042","url":null,"abstract":"<div><h3>Aims</h3><p>The clinical utility of waist-to-height ratio (WHtR) in predicting cardiometabolic risk factors (CMRFs) and subclinical markers of cardiovascular disease remains controversial. We aimed to compare the utility of WHtR with waist circumference (WC) and body mass index (BMI) in identifying children and adolescents (youths) at risk for cardiometabolic outcomes, including clustered CMRFs, high carotid intima-media thickness (cIMT), and arterial stiffness (assessed as high pulse wave velocity, PWV).</p></div><div><h3>Methods</h3><p>We analyzed data from 34,224 youths (51.0 % boys, aged 6–18 years) with CMRFs, 5004 (49.5 % boys, aged 6–18 years) with cIMT measurement, and 3100 (56.4 % boys, aged 6–17 years) with PWV measurement from 20 pediatric samples across 14 countries.</p></div><div><h3>Results</h3><p>WHtR, WC, and BMI z-scores had similar performance in discriminating youths with ≥3 CMRFs, with the area under the curve (AUC) (95 % confidence interval, CI)) ranging from 0.77 (0.75–0.78) to 0.78 (0.76–0.80) using the modified National Cholesterol Education Program (NCEP) definition, and from 0.77 (0.74–0.79) to 0.77 (0.74–0.80) using the International Diabetes Federation (IDF) definition. Similarly, all three measures showed similar performance in discriminating youths with subclinical vascular outcomes, with AUC (95 % CI) ranging from 0.67 (0.64–0.71) to 0.70 (0.66–0.73) for high cIMT (≥P95 values) and from 0.60 (0.58–0.66) to 0.62 (0.58–0.66) for high PWV (≥P95 values).</p></div><div><h3>Conclusions</h3><p>Our findings suggest that WHtR, WC, and BMI are equally effective in identifying at-risk youths across diverse pediatric populations worldwide. Given its simplicity and ease of use, WHtR could be a preferable option for quickly screening youths with increased cardiometabolic risk in clinical settings.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103042"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom","authors":"Mohammad Shafi Kuchay ,&nbsp;Scott Isaacs ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103034","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103034","url":null,"abstract":"<div><h3>Background and aims</h3><p>Thyroid hormones are important regulators of hepatic lipid homeostasis and whole-body energy expenditure. Recent evidence suggests that euthyroid individuals with metabolic dysfunction-associated steatohepatitis (MASH) develop intrahepatic hypothyroidism that promotes progression of MASH.</p></div><div><h3>Methods</h3><p>A literature search was performed with Medline (PubMed), Scopus and Google Scholar electronic databases from inception till March 2024, using the following keywords: hypothyroidism and nonalcoholic fatty liver disease; MASLD and thyroid function; intrahepatic hypothyroidism; TRβ agonists; and resmetirom. Relevant studies were extracted that described pathogenesis of MASH in the context of thyroid functions.</p></div><div><h3>Results</h3><p>In euthyroid individuals with MASH, there is decreased conversion of prohormone thyroxine (T4) to bioactive tri-iodothyronine (T3) and increased conversion of T4 to inactive metabolite reverse T3 (rT3). Consequently, reduced levels of T3 results in impaired intrahepatic TRβ signaling, a state of intrahepatic hypothyroidism, which promotes progression of MASH. Hepatic TRβ activation leads to metabolically beneficial effects in the liver including mitochondrial fatty acid uptake and β-oxidation, mitochondrial biogenesis, increasing surface low-density lipoprotein (LDL) receptor density and lowering of circulatory LDL-cholesterol. In recent years, selective thyroid hormone mimetics that exhibit TRβ-selective binding and liver-selective uptake have been designed. Resmetirom, a liver-specific thyromimetic, improves intrahepatic TRβ signaling and in clinical trials significantly improved liver inflammation, fibrosis and lipid profile in patients with MASH.</p></div><div><h3>Conclusions</h3><p>In euthyroid individuals with MASH, development of intrahepatic hypothyroidism results in further progression of the disease. In clinical trials, resmetirom treatment results in a significant improvement in steatosis, inflammation and fibrosis and is the first drug approved by the US Food and Drug Administration (FDA) for the treatment of noncirrhotic MASH with moderate to advanced fibrosis.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103034"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140842709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Graves’ disease and the risk of five autoimmune diseases: A Mendelian randomization and colocalization study","authors":"Tao Su ,&nbsp;Ying Gan ,&nbsp;Shulin Ma ,&nbsp;Hongzhen Wu ,&nbsp;Shilin Lu ,&nbsp;Min Zhi ,&nbsp;Bao Wang ,&nbsp;Yi Lu ,&nbsp;Jiayin Yao","doi":"10.1016/j.dsx.2024.103023","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103023","url":null,"abstract":"<div><h3>Background</h3><p>Epidemiological studies have consistently demonstrated a high prevalence of concurrent autoimmune diseases in individuals with Graves' disease (GD).</p></div><div><h3>Objective</h3><p>The objective of this study is to establish a causal association between GD and autoimmune diseases.</p></div><div><h3>Methods</h3><p>We employed a two-sample Mendelian randomization (MR) to infer a causal association between GD and five autoimmune diseases, namely rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Crohn's disease (CD), ulcerative colitis (UC), and amyotrophic lateral sclerosis (ALS), in the East Asian and European population. Genetic correlations were explored through linkage disequilibrium score regression analysis (LDSC). Finally, colocalization analyses were performed to investigate possible genetic foundations.</p></div><div><h3>Results</h3><p>Bidirectional MR analysis indicated that genetically predicted GD increased the risk of RA (Odds Ratio (OR): 1.34, 95 % Confidence Interval (CI): 1.21 to 1.47, P &lt; 0.001) and SLE (OR: 1.21, 95%CI: 1.08 to 1.35, P &lt; 0.001) in the East Asian population. In contrast, we found that genetically predicted RA (OR: 1.14, 95%CI: 1.05 to 1.24, P = 0.002) and SLE (OR: 1.10, 95%CI: 1.03 to 1.17, P = 0.003) were associated with a higher risk of GD. The results have been partially validated in European cohorts. Colocalization analysis suggested the potential existence of shared causal variants between GD and other autoimmune diseases. In particular, gene <em>ARID5B</em> may play an important role in the incidence of autoimmune diseases.</p></div><div><h3>Conclusion</h3><p>This study has confirmed that GD was associated with RA and SLE and found a possible key gene <em>ARID5B</em>. It may be necessary to strengthen detection to prevent the occurrence of comorbidities in clinical practice.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103023"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140818425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of diabetes from prediabetes in real world setting in South India","authors":"Vijay Viswanathan,&nbsp;Premalatha Murugan,&nbsp;Satyavani Kumpatla,&nbsp;Rizwana Parveen,&nbsp;Arutselvi Devarajan","doi":"10.1016/j.dsx.2024.103041","DOIUrl":"10.1016/j.dsx.2024.103041","url":null,"abstract":"<div><h3>Aim</h3><p>The aim was to explore the effect of lifestyle modification in a real world situation to prevent the progression to diabetes in India.</p></div><div><h3>Methods</h3><p>Participants who underwent OGTT from August 2017–2022 and were diagnosed as having Prediabetes (n = 200) were assigned into control (group1, n = 100) received standard care and intervention (group2, n = 100) received intensive counseling on physical activity (PA) and diet. PA included walking for 150 min/week and personalized advice based on the profession. OGTTs were repeated once every 6 months for 5 years and primary outcome was development of DM.</p></div><div><h3>Results</h3><p>The conversion rate was significantly higher in the control group than the intervention group (44.6 vs.7.9 %, p &lt; 0.0001). Individuals who reverted back to normal was significantly higher in Group2 compared to Group1 (34.9 vs.6.2 %; p &lt; 0.001). A significant increase in weight, BMI and waist circumference in group1 and significant reduction in glucose and HbA1c was noted in group2. Mean (95%CI) survival time for Group1 was 25.4 (20.8–29.9) and Group2 was 36.4months (32.6–40.1; p &lt; 0.001). The factors which influenced the conversion of prediabetes to DM were averaged BMI, fasting and 2hr glucose levels of all follow up visit measurements.</p></div><div><h3>Conclusion</h3><p>We can prevent diabetes in individuals with prediabetes using real world strategies in India.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103041"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141042864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensive or liberal glucose control in intensive care units for septic patients? A meta-analysis of randomized controlled trials","authors":"Jiahao Meng ,&nbsp;Xi Li ,&nbsp;Yifan Xiao ,&nbsp;Hang Tang ,&nbsp;Pan Liu ,&nbsp;Yumei Wu ,&nbsp;Yilin Xiong ,&nbsp;Shuguang Gao","doi":"10.1016/j.dsx.2024.103045","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103045","url":null,"abstract":"<div><h3>Objective</h3><p>To compare the clinical outcomes of intensive glucose control and liberal glucose control for septic patients in intensive care unit.</p></div><div><h3>Methods</h3><p>The databases of PubMed, Cochrane Library, Embase and Web of Science were searched systematically from inception to November 27, 2023 to identify trials involving a randomized comparison between intensive and liberal glucose control for septic patients in intensive care unit.</p></div><div><h3>Results</h3><p>A total of 14 randomized controlled trials involving 6226 patients were finally included. There was no statistically significant difference observed between intensive glucose control and liberal glucose control in terms of all-cause mortality, the need for renal replacement, vasopressor-free and mechanical ventilation-free days, and length of hospital stay. However, it is noteworthy that intensive glucose control exhibited a statistically higher risk of severe hypoglycemia (RR 2.66; 95%CI 1.85 to 3.83), need for blood transfusion (RR 1.12; 95%CI 1.01 to 1.23), and statistically prolonged length of stay in the ICU (MD 1.67; 95%CI 0.22 to 3.12) compared to liberal glucose control. Nevertheless, sensitivity analysis revealed that the need for blood transfusion and length of stay in the intensive care unit were not robust.</p></div><div><h3>Conclusions</h3><p>Both intensive and liberal glucose control had comparable effects on improving patient outcomes, but intensive glucose control carried a higher risk of severe hypoglycemia.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103045"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001061/pdfft?md5=da3a31247c56eb9e883792980aa4dc67&pid=1-s2.0-S1871402124001061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent effect of tart cherry on selected cardiometabolic risk factors: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials","authors":"Mostafa Norouzzadeh ,&nbsp;Minoo Hasan Rashedi ,&nbsp;Hossein Shahinfar ,&nbsp;Seyedeh Tayebeh Rahideh","doi":"10.1016/j.dsx.2024.103026","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103026","url":null,"abstract":"<div><h3>Aims</h3><p>This study aimed to clarify the effectiveness of tart cherries on anthropometric, lipid, and glycemic indices. We also aimed to clarify the appropriate dosage for this effect and suggest directions for future studies.</p></div><div><h3>Methods</h3><p>PubMed, Scopus, and Web of Science were searched until May 2022. Twelve eligible trials were included. The pooled results were reported as weighted mean differences (WMD) and 95 % confidence intervals (CIs). The Cochrane risk of bias and GRADE tools were used to assess the risk of bias and certainty of the evidence, respectively.</p></div><div><h3>Results</h3><p>Tart cherry generally showed no significant effects on cardiometabolic risk factors. But subgroup analysis revealed that tart cherry significantly lowered total cholesterol (WMD: –0.33 mmol/l; 95 % CI: –0.55, –0.10), triglyceride (WMD: –0.19 mmol/l; 95 % CI: –0.26, –0.12), and low-density lipoprotein cholesterol (WMD: –0.36 mmol/l; 95 % CI: –0.58, –0.14), in unhealthy populations. Additionally, subgroup analysis indicated that the favorable effects of tart cherry were more pronounced in a single dose, longer duration, elderly, and obese individuals. Dose-response analysis revealed that 20 ml concentrate has the greatest effect in reducing total cholesterol (WMD: –0.40 mmol/l; 95 % CI: –0.61, –0.19), triglyceride (WMD: –0.23 mmol/l; 95 % CI: –0.33, –0.13), and elevating high-density lipoprotein cholesterol (WMD: 0.20 mmol/l; 95 % CI: 0.17, 0.22).</p></div><div><h3>Conclusions</h3><p>Tart cherry supplementation did not have significant effects on anthropometric and glycemic indices, but can improve lipid profile, especially in a single dose, longer duration, and in elderly, obese, and unhealthy individuals.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103026"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140950141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}